These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27821317)

  • 1. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
    Heil J; Schaefgen B; Sinn P; Richter H; Harcos A; Gomez C; Stieber A; Hennigs A; Rauch G; Schuetz F; Sohn C; Schneeweiss A; Golatta M
    Eur J Cancer; 2016 Dec; 69():142-150. PubMed ID: 27821317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.
    Heil J; Kümmel S; Schaefgen B; Paepke S; Thomssen C; Rauch G; Ataseven B; Große R; Dreesmann V; Kühn T; Loibl S; Blohmer JU; von Minckwitz G
    Br J Cancer; 2015 Dec; 113(11):1565-70. PubMed ID: 26554654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    Heil J; Sinn P; Richter H; Pfob A; Schaefgen B; Hennigs A; Riedel F; Thomas B; Thill M; Hahn M; Blohmer JU; Kuemmel S; Karsten MM; Reinisch M; Hackmann J; Reimer T; Rauch G; Golatta M
    BMC Cancer; 2018 Aug; 18(1):851. PubMed ID: 30144818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
    Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
    Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
    Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
    Heil J; Pfob A; Sinn HP; Rauch G; Bach P; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Ditsch N; Rody A; Große R; van Mackelenbergh M; Reinisch M; Karsten M; Golatta M;
    Ann Surg; 2022 Mar; 275(3):576-581. PubMed ID: 32657944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up.
    Huang ML; Speer M; Dogan BE; Rauch GM; Candelaria RP; Adrada BE; Hess KR; Yang WT
    AJR Am J Roentgenol; 2017 Apr; 208(4):916-922. PubMed ID: 28140609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications.
    Goldberg H; Zandbank J; Kent V; Leonov-Polak M; Livoff A; Chernihovsky A; Guindy M; Evron E
    Eur J Surg Oncol; 2017 Aug; 43(8):1415-1420. PubMed ID: 28526187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
    Schaefgen B; Mati M; Sinn HP; Golatta M; Stieber A; Rauch G; Hennigs A; Richter H; Domschke C; Schuetz F; Sohn C; Schneeweiss A; Heil J
    Ann Surg Oncol; 2016 Mar; 23(3):789-95. PubMed ID: 26467456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.